PharmaJet Poster Presentation at Cancer Immunotherapy Conference Highlights How Needle-free Technology is Enhancing Oncology ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia ...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, ...

Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and ...

Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells with improved efficacy against solid tumors, announced today that it will present new data on its ...

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) An ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.

ALX Oncology to present results from phase 1b/2 trial of evorpacept in combo with zanidatamab at SABCS 2024: South San Francisco, California Tuesday, November 5, 2024, 12:00 Hrs [ ...

Both students are active in APSU’s Print Club, a student organization focused on printmaking. They create limited-edition ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...